House Medicare bill retains Rep. Thomas' investigational device payment language.
This article was originally published in The Gray Sheet
Executive Summary
HOUSE MEDICARE BILL RETAINS REP. THOMAS' INVESTIGATIONAL DEVICE PROVISION after the House Rules Committee decided Oct. 18 to disallow broader language providing Medicare reimbursement for all investigational devices with an approved investigational device exemption. The Medicare reform bill passed by the House Oct. 19 reverts to language introduced by Rep. William Thomas (R-Calif.) in June (HR 1744) and subsequently incorporated into the original draft of the House Medicare bill. The final House measure would allow Medicare coverage of investigational devices only if the device has an approved IDE and is used in place of an approved device.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.